Published in AIDS Weekly, June 30th, 2008
"The proposed model and methods are applied to analyse the data from PACTG345 study. Population and individual patterns of change of CD4+ counts and a reference band are obtained," wrote H. Liang and colleagues, University of Rochester.
The researchers concluded: "Our results indicate that treatment with high-dose ritonavir is significantly superior compared with low-dose ritonavir."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.